SPRY — ARS Pharmaceuticals, Inc.

Summary of ARS Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total revenue for Q1 2026 was $22.7 million, including:
  • $17.5 million in U.S. net product revenue for neffy (3x volume of prescriptions year-over-year).
  • $2.5 million from collaboration agreements and $2.7 million from supply revenue.
• R&D expenses were $4.3 million; SG&A expenses totaled $72.2 million.
• Cash position at the end of Q1 was $201 million, providing flexibility for operations and growth.
• Gross to net retention remains in the low to mid-50% range, targeting approximately 50% at steady state.

2. Strategic Updates and Business Highlights:

• Focus areas include expanding access, improving affordability, and increasing prescriber adoption of neffy.
• Achieved 90% commercial coverage, with 57% of this without prior authorization.
• Notable developments include:
  • Florida added neffy to its unrestricted Medicaid formulary.
  • CVS Caremark proposal nearing final approval, which could significantly enhance patient access.
  • Launched a new program allowing patients to purchase neffy at a $199 cash price at retail pharmacies, addressing previous high out-of-pocket costs.
• Expanded sales force to 148 representatives to enhance engagement with high-volume prescribers.
• Pediatric label expansion by the FDA is expected to drive adoption among younger patients.

3. Forward Guidance and Outlook:

• Anticipate continued revenue growth, especially in the second half of 2026, driven by back-to-school season and improved access.
• Expect to reach cash flow breakeven by mid-2027, with reduced losses anticipated in the second half of 2026.
• The company is focused on optimizing spending towards high-return commercial activities.

4. Bad News, Challenges, or Points of Concern:

• The first quarter is typically the lowest volume period for epinephrine, which may skew perceptions of growth.
• The prior authorization process remains a barrier to prescribing, causing friction in adoption.
• There are risks associated with the timing of CVS Caremark’s approval and the potential impact on market share growth.
• The company is still working to penetrate the electronic refill market, which presents additional challenges.

5. Notable Q&A Insights:

• Confidence expressed regarding CVS Caremark approval and its expected impact on market share, especially in conjunction with back-to-school season.
• Discussion on the potential for refill contributions to significantly boost volumes as families renew prescriptions for the school year.
• The company is actively working to broaden prescribing patterns beyond high-decile accounts, with over 28,000 physicians already prescribing neffy.
• Insights into the automated conversion process for denied claims, which aims to simplify access and reduce prescription abandonment rates.

Overall, ARS Pharmaceuticals is positioned for growth with strategic initiatives aimed at improving access and adoption of neffy, despite facing challenges related to prior authorization and market dynamics.